BI
BVF Inc Portfolio holdings
AUM
$2.8B
This Quarter Return
-16.69%
1 Year Return
+17.96%
3 Year Return
+404.14%
5 Year Return
+563.41%
10 Year Return
+5,885.83%
AUM
$2.07B
AUM Growth
+$2.07B
(-17%)
Cap. Flow
+$111M
Cap. Flow
% of AUM
5.36%
Top 10 Holdings %
Top 10 Hldgs %
44.14%
Holding
87
New
6
Increased
22
Reduced
12
Closed
8
Top Buys
| 1 |
MoonLake Immunotherapeutics
MLTX
|
$114M |
| 2 |
Ionis Pharmaceuticals
IONS
|
$47.3M |
| 3 |
Repare Therapeutics
RPTX
|
$34M |
| 4 |
Cullinan Oncology
CGEM
|
$27.4M |
| 5 |
CNTA
Centessa Pharmaceuticals
CNTA
|
$25M |
Top Sells
| 1 |
argenx
ARGX
|
$99.7M |
| 2 |
Galapagos
GLPG
|
$64.9M |
| 3 |
Protagonist Therapeutics
PTGX
|
$24.3M |
| 4 |
CALA
Calithera Biosciences, Inc
CALA
|
$21.7M |
| 5 |
NGM
NGM Biopharmaceuticals, Inc. Common Stock
NGM
|
$14.6M |
Sector Composition
| 1 | Healthcare | 99.1% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
76
Voyager Therapeutics
VYGR
$207M
| $827K | 0.04% |
140,000
-1,049,100
| -88% | -$6.2M |
|
77
X4 Pharmaceuticals
XFOR
$70.3M
| $818K | 0.04% |
847,879
| – | – |
|
78
Rezolute
RZLT
$625M
| $616K | 0.03% |
190,815
| – | – |
|
|
NEUP
79
Neuphoria Therapeutics Inc. Common Stock
NEUP
$23.1M
| $555K | 0.03% |
80,971
| – | – |
|
80
Acumen Pharmaceuticals
ABOS
$82.4M
| – | – |
-289,663
| Closed | -$1.13M |
|
|
81
argenx
ARGX
$43.7B
| – | – |
-316,204
| Closed | -$99.7M |
|
82
Day One Biopharmaceuticals
DAWN
$768M
| – | – |
-809,282
| Closed | -$8.03M |
|
|
83
Galapagos
GLPG
$2.05B
| – | – |
-1,046,283
| Closed | -$64.9M |
|
|
NGM
84
DELISTED
NGM Biopharmaceuticals, Inc. Common Stock
NGM
| – | – |
-955,000
| Closed | -$14.6M |
|
|
JNCE
85
DELISTED
Jounce Therapeutics, Inc. Common Stock
JNCE
| – | – |
-126,797
| Closed | -$861K |
|
|
RDUS
86
DELISTED
Radius Health, Inc.
RDUS
| – | – |
-378,000
| Closed | -$3.34M |
|
|
GNCA
87
DELISTED
Genocea Biosciences, Inc.
GNCA
| – | – |
-4,012,404
| Closed | -$5.02M |
|